HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Vir Biotechnology (NASDAQ:VIR) and maintained a price target of $110.
May 24, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Vir Biotechnology and maintained a price target of $110, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in Vir Biotechnology, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100